Skip to main content
. Author manuscript; available in PMC: 2013 Nov 19.
Published in final edited form as: Leukemia. 2013 May 14;27(10):10.1038/leu.2013.151. doi: 10.1038/leu.2013.151

Figure 4. The combination ABT-263 and PP242 triggers apoptosis of leukemic but not normal CD34+ progenitor cells, and overcomes microenvironment-induced TKI resistance.

Figure 4

(A) Clonogenic and/or (B) survival analyses (mean ± SEM, p ≤ 0.01) of untreated (DMSO) and drug (ABT-263 and/or PP242)-treated CD34+ BM progenitors from CML-CP, CML-BC patients and/or healthy individuals (NBM: normal bone marrow). (C) Survival analysis (mean ± SEM; n=3) shows effect of extrinsic drug-resistance signals provided by hTERT+ stromal cell-conditioned medium (CM) on the pro-apoptotic activity of Imatinib and ABT263/PP242 in Ph+ LAMA84 cells.